日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors.

以“配体优先”为导向的选择性共价 JNK2/3 抑制剂策略

Wydra Valentin R, Plank Nicole, Zwirner Stefan, Selig Roland, Rasch Alexander, Masberg Benedikt, Lämmerhofer Michael, Zender Lars, Koch Pierre, Albrecht Wolfgang, Laufer Stefan

Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one MKK4 Inhibitor.

发现首个高选择性 1,4-二氢吡啶并[3,4-b]吡嗪-3(2H)-酮 MKK4 抑制剂

Katzengruber Leon, Sander Pascal, Zwirner Stefan, Rasch Alexander, Eberlein Eric, Selig Roland, Albrecht Wolfgang, Zender Lars, Laufer Stefan A

First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.

首创的 MKK4 抑制剂可增强肝脏再生并预防肝衰竭

Zwirner Stefan, Abu Rmilah Anan A, Klotz Sabrina, Pfaffenroth Bent, Kloevekorn Philip, Moschopoulou Athina A, Schuette Svenja, Haag Mathias, Selig Roland, Li Kewei, Zhou Wei, Nelson Erek, Poso Antti, Chen Harvey, Amiot Bruce, Jia Yao, Minshew Anna, Michalak Gregory, Cui Wei, Rist Elke, Longerich Thomas, Jung Birgit, Felgendreff Philipp, Trompak Omelyan, Premsrirut Prem K, Gries Katharina, Muerdter Thomas E, Heinkele Georg, Wuestefeld Torsten, Shapiro David, Weissbach Markus, Koenigsrainer Alfred, Sipos Bence, Ab Eiso, Zacarias Magdalena Ortiz, Theisgen Stephan, Gruenheit Nicole, Biskup Saskia, Schwab Matthias, Albrecht Wolfgang, Laufer Stefan, Nyberg Scott, Zender Lars